Aldesleukin biosimilar - Amega BiotechAlternative Names: IL-2 - Amega Biotech; Recombinant interleukin 2 biosimilar - Amega Biotech; Recombinant interleukin-2 - Amega Biotech
Latest Information Update: 15 Aug 2013
At a glance
- Originator Amega Biotech
- Class Antineoplastics; Interleukins; Recombinant proteins
- Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Malignant melanoma; Renal cancer
Most Recent Events
- 15 Aug 2013 Investigation in Renal cancer in Argentina (Parenteral)
- 15 Aug 2013 Investigation in Malignant melanoma in Argentina (Parenteral)